Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apolipoprotein A1 and B.

Allan D Sniderman1, Santica M Marcovina

  • 1Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7.22, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada. allansniderman@hotmail.com

Clinics in Laboratory Medicine
|November 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Cardiovascular Prevention in the Era of AI.

European journal of preventive cardiology·2026
Same author

Direct Lp(a)-C measurements provide evidence for Apo(a) isoform-dependent cholesterol composition of Lp(a).

Journal of lipid research·2026
Same author

Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

JAMA·2026
Same author

Analytical validation of a direct lipoprotein(a)-cholesterol assay.

Journal of lipid research·2026
Same author

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies.

Current cardiology reports·2026
Same author

Effect of weight loss through dietary interventions on cardiometabolic health in older adults.

International journal of obesity (2005)·2025

Apolipoprotein B (apoB) and A-1 (apoA-1) are better than traditional cholesterol measures for assessing vascular disease risk and monitoring lipid-lowering therapy effectiveness in laboratory practice.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Chemistry
  • Lipid Metabolism

Background:

  • Conventional cholesterol indices (e.g., LDL-C, HDL-C) have limitations in assessing lipoprotein-related risk.
  • Vascular disease risk is complex and influenced by various lipoprotein components.
  • Monitoring the effectiveness of lipid-lowering therapies requires precise and informative biomarkers.

Purpose of the Study:

  • To review evidence supporting apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) as superior laboratory analytes.
  • To evaluate apoB and apoA-1 for assessing lipoprotein-related vascular disease risk.
  • To determine the utility of apoB and apoA-1 in measuring the adequacy of low-density lipoprotein-lowering therapy.

Main Methods:

  • Systematic review of existing scientific literature and clinical studies.

Related Experiment Videos

  • Comparative analysis of apolipoprotein assays versus conventional lipid panels.
  • Evaluation of clinical outcomes associated with apoB and apoA-1 levels.

    • Main Results:

    • Apolipoprotein B (apoB) levels are a more accurate marker of atherogenic lipoprotein particles than LDL-C.
    • Apolipoprotein A-1 (apoA-1) levels correlate better with cardioprotective HDL particles.
    • ApoB and apoA-1 provide superior risk stratification for vascular disease and better assessment of therapeutic response.

    Conclusions:

    • Apolipoprotein B and A-1 offer enhanced diagnostic and prognostic value in laboratory practice.
    • Routine use of apoB and apoA-1 assays can improve cardiovascular risk assessment.
    • These apolipoproteins are valuable tools for optimizing lipid-lowering treatment strategies.